Pluristem Updates Cell Manufacturing Industry on Its Proprietary 3D Cell Expansion Technology at Industry Conference

Pluristem Updates Cell Manufacturing Industry on Its Proprietary 3D Cell
Expansion Technology at Industry Conference

HAIFA, Israel, Jan. 22, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc.
(Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell
therapies, announced today that Senior Scientists at Pluristem will be
presenting updated developments relating to the company's proprietary 3D cell
expansion technology. These innovations will be implemented in Pluristem's new
state-of-the-art manufacturing facility for expansion of placental-derived
mesenchymal-like Adherent Stromal Cells (ASCs).

The presentations will take place at Engineering Conferences International's
Scale-Up and Manufacturing of Cell-Based Therapies II Conference to be held
January 21-23, 2013 at the Hyatt Regency Mission Bay Spa and Marina in San
Diego, California.

Ohad Karnieli PhD, MBA and VP of Development at Pluristem will give an oral
presentation entitled, "Bioreactors in Cell Therapy, the Advantages of
High-Throughput Culturing Technologies and the Downstream Challenges". During
this talk, Dr. Karnieli will present Pluristem's new production line and
demonstrate how the company has drawn on its vast experience in
high-throughput culturing to solve many of the problems related to the mass
production of ASCs. Dr. Karnieli's presentation will be madeavailableat the
company's website
for the next 30 days.

Eytan Abraham PhD and Product Innovation Research Manager at Pluristem will
give a poster presentation entitled, "From Gene Expression to In Vivo Models -
Characterization and Potential Therapeutic Properties of Placenta Derived
Mesenchymal-Like Adherent Stromal Cells". In this poster, Dr. Abraham will be
addressing the specific changes that occur in gene regulation and protein
secretion when ASCs are grown in a 3D culturing phase and the biological
changes and therapeutic advantages of implementing this technology in the mass
expansion of ASCs use.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) is a leading developer
of placenta-based cell therapies. The Company's patented PLX (PLacental
eXpanded) cells are a drug delivery platform that releases a cocktail of
therapeutic proteins in response to a host of local and systemic inflammatory
and ischemic diseases. PLX cells are grown using the company's proprietary 3D
micro-environmental technology and are an "off-the-shelf" product that
requires no tissue matching prior to administration. Pluristem is focusing on
the development of PLX cells administered locally to potentially treat
systemic diseases and potentially obviating the need to use the intravenous

Pluristem has a strong patent and patent applications portfolio, company-owned
GMP certified manufacturing and research facilities, strategic relationships
with major research institutions and a seasoned management team. For more
information visit, the content of which is not part of this
press release.

The Pluristem Therapeutics Inc. logo is available at

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995 and federal securities laws. For example, we are using forward-looking
statements when we discuss that developments relating to the our proprietary
3D cell expansion technology will be implemented in our new state-of-the-art
manufacturing facility for expansion of placental-derived-like Adherent
Stromal Cells (ASCs). These forward-looking statements are based on the
current expectations of the management of Pluristem only, and are subject to a
number of factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements. The
following factors, among others, could cause actual results to differ
materially from those described in the forward-looking statements: changes in
technology and market requirements; we may encounter delays or obstacles in
launching and/or successfully completing our clinical trials; our products may
not be approved by regulatory agencies, our technology may not be validated as
we progress further and our methods may not be accepted by the scientific
community; we may be unable to retain or attract key employees whose knowledge
is essential to the development of our products; unforeseen scientific
difficulties may develop with our process; our products may wind up being more
expensive than we anticipate; results in the laboratory may not translate to
equally good results in real surgical settings; results of preclinical studies
may not correlate with the results of human clinical trials; our patents may
not be sufficient; our products may harm recipients; changes in legislation;
inability to timely develop and introduce new technologies, products and
applications; loss of market share and pressure on pricing resulting from
competition, which could cause the actual results or performance of Pluristem
to differ materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Pluristem undertakes no
obligation to publicly release any revisions to these forward-looking
statements to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. For a more detailed
description of the risks and uncertainties affecting Pluristem, reference is
made to Pluristem's reports filed from time to time with the Securities and
Exchange Commission.

CONTACT: Pluristem Therapeutics Inc.:
         William Prather R.Ph., M.D. Sr. VP Corporate Development
         Daya Lettvin
         Investor & Media Relations Director

Pluristem Therapeutics Inc. Logo
Press spacebar to pause and continue. Press esc to stop.